Page 25 - Read Online

Page 12 of 12 Kirakli et al. J Cancer Metastasis Treat 2019;5:10 I http://dx.doi.org/10.20517/2394-4722.2018.73

51. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-
cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol
2014;32:3810-6.
52. Oehlke O, Wucherpfennig D, Fels F, Frings L, Egger K, et al. Whole brain irradiation with hippocampal sparing and dose escalation on
multiple brain metastases: local tumour control and survival. Strahlenther Onkol 2015;191:461-9.
53. Gondi V, Deshmukh S, Brown PD, Wefel JS, Tome WA, et al. Preservation of neurocognitive function with conformal avoidance of the
hippocampus during whole-brain radiotherapy for brain metastases: preliminary results of phase III trial. Available from: https://www.astro.
org/ASTRO/media/ASTRO/Meetings%20and%20Education/PDFs/BOA18/FullTextAbstracts.pdf. [Last accessed on 24 Jan 2019]
54. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, et al. Memantine for the prevention of cognitive dysfunction in patients receiving
whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013;15:1429-37.
55. ClinicalTrials.gov. Memantine hydrochloride and whole-brain radiotherapy with or without hippocampal avoidance in reducing
neurocognitive decline in patients with brain metastases. Available from: https://clinicaltrials.gov/ct2/show/NCT02360215?cond=Memantin
e+Hippocampus&rank=1. [Last accessed on 17 Jan 2019]
56. Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, et al. Stereotactic radiosurgery for patients with multiple brain metastases
(JLGK0901): a multi-institutional prospective observational study. Lancet Oncol 2014;15:387-95.
57. Yamamoto M, Serizawa T, Higuchi Y, Sato Y, Kawagishi J, et al. A multi-institutional prospective observational study of stereotactic
radiosurgery for patients with multiple brain metastases (JLGK0901 study update): irradiation-related complications and long-term
maintenance of mini-mental state examination scores. Int J Radiat Oncol Biol Phys 2017;99:31-40.
58. ClinicalTrials.gov. Stereotactic radiosurgery compared with whole brain radiotherapy (WBRT) for 5-15 brain metastases. Available from:
https://clinicaltrials.gov/ct2/show/NCT03550391. [Last accessed on 24 Jan 2019]
59. ClinicalTrials.gov. Whole brain radiation versus stereotactic radiation (SRS) in patients with 5-20 brain metastases: a phase III, randomized
clinical trial. Available from: https://clinicaltrials.gov/ct2/show/NCT03075072?term=NCT03075072&rank=1. [Last accessed on 17 Jan
2019]
60. Eaton BR, LaRiviere MJ, Kim S, Prabhu RS, Patel K, et al. Hypofractionated radiosurgery has a better safety profile than single fraction
radiosurgery for large resected brain metastases. J Neurooncol 2015;123:103-11.
61. Loganadane G, Hendriks L, Le Péchoux C, Levy A. The current role of whole brain radiation therapy in non-small cell lung cancer patients.
J Thorac Oncol 2017;12:1467-77.
62. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, et al. Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain
metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 2012;77:556-60.
63. Iuchi T, Shingyoji M, Sakaida T, Hatano K, Nagano O, et al. Phase II trial of gefitinib alone without radiation therapy for Japanese patients
with brain metastases from EGFR-mutant lung adenocarcinoma. Lung Cancer 2013;82:282-7.
64. Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and
asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol 2013;24:993-9.
65. Wen PY. Controversies in neuro-oncology: role of whole-brain radiation therapy in the treatment of newly diagnosed brain metastases.
Neuro Oncol 2015;17:915.
66. Magnuson WJ, Lester-Coll NH, Wu AJ, Yang TJ, Lockney NA, et al. Management of brain metastases in tyrosine kinase inhibitor-
naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol
2017;35:1070-7.
67. Costa DB, Shaw AT, Ou SH, Solomon BJ, Riely GJ, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged
non-small-cell lung cancer and brain metastases. J Clin Oncol 2015;33:1881-8.
68. ASCO. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): primary results of the
global phase III ALEX study. Available from: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA9008. [Last accessed on 24
Jan 2019]
69. Olmez I, Donahue BR, Butler JS, Huang Y, Rubin P, et al. Clinical outcomes in extracranial tumor sites and unusual toxicities with
concurrent whole brain radiation (WBRT) and erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain
metastasis. Lung Cancer 2010;70:174-9.
70. Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, et al. Pembrolizumab for patients with melanoma or non-small-cell lung
cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 2016;17:976-83.
71. Kanai O, Fujita K, Okamura M, Nakatani K, Mio T. Severe exacerbation or manifestation of primary disease related to nivolumab in non-
small-cell lung cancer patients with poor performance status or brain metastases. Ann Oncol 2016;27:1354-6.
72. Chen L, Douglass J, Kleinberg L, Ye X, Marciscano AE, et al. Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for
brain metastases in non-small cell lung Cancer, melanoma, and renal cell carcinoma. Int J Radiat Oncol Biol Phys 2018;100:916-25.
73. Hubbeling HG, Schapira EF, Horick NK, Goodwin KEH, Lin JJ, et al. Safety of combined PD-1 pathway inhibition and intracranial
radiation therapy in non-small cell lung cancer. J Thorac Oncol 2018;13:550-8.